SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-252464
Filing Date
2023-10-06
Accepted
2023-10-06 17:26:59
Documents
12
Period of Report
2023-10-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d503515d8k.htm   iXBRL 8-K 89807
  Complete submission text file 0001193125-23-252464.txt   223009

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tals-20231006.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20231006_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20231006_pre.xml EX-101.PRE 11255
6 EXTRACTED XBRL INSTANCE DOCUMENT d503515d8k_htm.xml XML 3346
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 231314991
SIC: 2836 Biological Products, (No Diagnostic Substances)